Autologous Stem Cell Transplantation in Multiple Myeloma: Is It Still the Gold Standard?
FDA Issues Partial Clinical Hold on Lorigerlimab Trial in Gynecologic Cancers: The FDA has put a clinical hold on Lorigerlimab trials due to safety issues, including a treatment-related death.
Refining Management of Immune-Checkpoint Inhibitor Toxicities in Melanoma: There’s ongoing discussion around management refinement of immune checkpoint inhibitor toxicity in melanoma treatment.
FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma: The FDA has granted fast track designation to SRN-101, targeting recurrent high-grade glioma treatment.
Novel Small Molecule Shows Early Activity in Pretreated Multiple Myeloma: A novel small molecule has demonstrated early activity in multiple myeloma patients who have undergone prior treatment.
Comparing Quality of Life Outcomes with Protons vs Photons in OPSCC: The patients’ quality of life outcomes differ when OPSCC is treated with protons as opposed to photons.
